Vivacelle Bio Inc.

Vivacelle Bio Inc. is a clinical stage biotechnology company based in Kansas City, MO, focused on developing innovative products to enhance the survivability of critically-ill patients. Their patented phospholipid nanoparticle technology allows for the design of products that address conditions such as hypovolemia and hypotension, with the aim of improving tissue perfusion and preventing organ failure. With FDA clearance for phase IIa clinical trials on two of their products, Vivacelle Bio is at the forefront of creating a new paradigm in fluid resuscitation and has a pipeline of additional products in development for various medical applications. Vivacelle Bio Inc. utilizes phospholipid nanoparticles, composed of naturally-occurring phospholipids, to create micelles and liposomes of different sizes that possess unique properties beneficial in critical illness. Their products, such as VBI-S for the treatment of hypovolemia and hypotension of septic shock, have shown promising results in clinical trials. By absorbing and releasing nitric oxide, their phospholipid nanoparticles effectively reduce reperfusion injury while maintaining the essential functions of nitric oxide in the body. With a focus on saving lives and improving patient outcomes, Vivacelle Bio is dedicated to advancing the field of fluid resuscitation and developing innovative solutions for critical care.

Generated from the website